Morpholinyl and pyrrolidinyl analogs

A compound of Formula (I):

• wherein
• R1 is:
• A is (CH2)n;
• n is 1 or 2;
• the group (a) may be unsubstituted or substituted by one, two, or three substituents chosen from:
• halo, OC1-3 alkyl, OH, CN, C(O)OH, NR7R8, OCF3, C(O)NR9R10, SO2C1-3 alkyl, SO2C3-6 cycloalkyl, SO2-phenyl, SO2NR9R10, CF3, and NO2;
• R2 is hydrogen, halo, OC1-3 alkyl, NHC(O)C1-3 alkyl, NHSO2C1-3alkyl, NHSO2-phenyl, NHC(O)C3-6 cycloalkyl, or NHC(O)-phenyl;
• R3 is C1-3 alkyl or C3-6 cycloalkyl;
• R4, R5, and R6 are independently hydrogen or CH3;
• R7 and R8 are independently hydrogen, C(O)C1-3 alkyl, C(O)C3-6 cycloalkyl, C(O)-phenyl,
• C1-6 alkyl, phenyl, SO2C1-3 alkyl, SO2C3-6 cycloalkyl, SO2-phenyl, or C(O)NHC1-3 alkyl;
• R9 and R10 are independently hydrogen, C1-3 alkyl, C3-6 cycloalkyl, phenyl;
• or taken together R9 and R10 may form a 5 to 7 member ring optionally containing one or two heteroatoms chosen from O, N, and S;
• X is O or a bond;
• B is:
• R12 is hydrogen, C1-3 alkyl, CH2CN, (CH2)m(O)CH3, CH2C(O)NH2, or (CH2)mOH;
• R13 is hydrogen, halo, C1-3 alkyl, CF3, or OC1-3 alkyl;
• m is 2 or 3;
• R14 is hydrogen, halo, C1-3 alkyl, OC1-3 alkyl, OCF3, CF3, C(O)NR15R16, or C(O)OC1-3 alkyl;
• and
• R15 and R16 are independently hydrogen, C1-3 alkyl, C3-6 cycloalkyl, or phenyl;
• or a pharmaceutically acceptable salt thereof.